drugset
drugset / Trial / NCT06749860

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

NCT06749860 ↗

Phase 2 Recruiting 58 enrolled Shanghai Pulmonary Hospital, Shanghai, China
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn ifDisitamab Vedotin in combination with tislelizumab and bevacizumab can treat in locally advanced or metastatic non-small cell lung cancer patients with HER2 mutation/amplification/expression. The main questions it aims to answer are: 1. objective response rate; 2. Progression-Free Survival; 3. Overall Survival; 4. Disease Control Rate; 5. Duration of Response.

Timeline

Start
2024-02-02
Primary completion
2026-06-06
Completion
2027-06-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 7.5 mg/kg Intravenous
Subject Disitamab Vedotin Monoclonal antibody 2 mg/kg Intravenous
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous

Indications

lung cancer